August 18-19, 2005
National Institute of Standards and Technology
This workshop is being jointly sponsored by the DNA Technologies Group/Biotechnology Division/Chemical Science and Technology Laboratory of the National Institute of Standards and Technology (NIST) and the Early Detection Research Network (EDRN) of the National Cancer Institute.
Progress in developing and validating biomarkers to detect cancers with high accuracy, sensitivity, and specificity is hampered by the lack of reproducibility and consistency. This is due in part to the lack of standard reagents and methods. The objectives of this workshop are to compare the performance characteristics of different analytical platforms, to assess the needs for standard methods, assays and reagents for cancer biomarker development and validation, and to make recommendations for the development of standard reference materials and standard operating procedures. This workshop will focus on the following areas:
- Methods and standards to quantitatively and reliably measure DNA methylation in clinical specimens,
- Standard proteomic reference materials for cancer biomarker discovery and validation and for cross-validation between laboratories and platforms, and
- Characteristics of clinical reference materials that can be used to accelerate the discovery and validation of cancer biomarkers.
Back to top